DNA　immunization technology is quite hot in the field of biotechnology recent years. It has been proved by scientists to have great significance in improving the effectiveness of immune procedure. Facing this brand new trend of development, pharmaceutical companies are expanding their business in this realm with different approaches, Direct Antibody Technology™ (DAT) , for instance.

The Direct Antibody Technology™ (DAT) is developed to produce custom polyclonal and biosimilar monoclonal antibodies. As a highly optimized service, this DNA immunization technology relies on a proprietary genetic immunization procedure utilizing plasmid DNA encoding the target protein of interest. The immunized hosts then produce the encoded protein and raise antibodies in vivo.

In order to succeed in genetic immunization, the cDNA-encoded protein must be secreted by the transfected cells in immunized animals or expressed on the surface of the transfected cells. Scientists directly introduce the gene in the form of a cDNA into an animal, which translates this cDNA into protein so as to stimulate an immune response against the foreign protein. As a result, synthesis and purification of protein immunogens are not necessary for this genetic immunization approach.

This Direct Antibody Technology™ maximizes the likelihood of producing and maintaining the native structure of the antigen. The foremost advantage of this antibody production approach is its high success rate in generation of high affinity antibody recognizing membrane proteins in their native conformation, unknown proteins, toxic proteins, insoluble proteins, proteins containing disulfide bonds, post-translational modified proteins, or large protein domains.

About Author

Creative Biolabs is a US biotech company focuses on the field of antibody production, such as guinea pig antibody and humanized antibody. As a trusted provider of the most cost-effective outsourcing solutions, Creative Biolabs has been serving a large number of clients from all over the world.